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Abstract
Background: We screened RARβ methylation in primary glioblastoma multiforme (GBM) and the results were evaluated 
based on the clinical data and treatment type.
Objective: The objective of  this study was to find new areas for the usage of  MS-HRM applications in the determination 
of  methylation levels in primary GBM samples and it shows the association of  RARβ methylation with the clinical outcome.
Methods: In our study, tumor samples were collected during surgical resection by the Department of  Neurosurgery. The 
clinical and radiologic data was carefully reviewed, compared, and evaluated with the histological results. The methylation 
status of  RARβ was determined by using MS-HRM.
Results: RARβ gene methylation was detected in 24 out of  40 cases (60%), with different quantitative methylation levels.
The mean survival time was 19 months form ethylated cases and 15 months for the non-methylated cases. The survival time 
of  the patients who received treatment was 25 months and the survival time of  the patients who received radiotherapy alone 
or where no treatment protocol applied was 15-20 months. Therefore, a significant difference in survival rates has been ob-
served (P<0.05). This study indicates a potential prognostic value for GBM treatment planning. 
Conclusion: Our study is the first study to investigate RARβ methylation in primary GBMs. We conclude that the RARβ 
gene could be a new prognostic and predictive candidate marker to designate the treatment protocol for primary GBMs.
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Introduction
Glioblastoma (WHO grade IV), or glioblastoma multi-
forme (GBM), is the most frequent and malignant form 
of  brain tumor, accounting for approximately 51% of  
all primary gliomas (CBTRUS, 2010). The median sur-
vival time is 12 months. Depending on clinical and bio-
logical differences, GBMs can be divided into two dis-
tinct subtypes: primary (or de novo) glioblastomas that 
develop without the presence of  any precursor neoplas-
tic lesion and manifest after a short clinical history; and 
secondary glioblastomas that develop from lower grade 
glial tumors13.
 
Methylation is one of  the most known and studied epi-
genetic mechanisms. It is the oldest and most widely 
used epigenetic mechanism used to identify expressions 
of  the cancer specific genes.  Many genes in glioblasto-
mas have epigenetic characteristics that include hyper-
methylation of  the MGMT, RASSF1A, p16/INK4A 
and p15/INK4. These hypermethylated genes have 
been reported as a marker for prognosis, treatment pro-
tocol selection and survival for GBM patients1,7.
Abnormal DNA methylation of  brain tumors was first 
discovered 20 years ago and previous methylation stud-
ies for candidate genes in brain tissue have concentrated 
on:
•  Cell cycle genes that include: RB, CDKN2A, CD-
KN2B, p73,  and PTEN
•  Genes which are important in cell-cell interactions 
that include: EMP3, E-Cadherin and RASSF1A
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•  DNA repair and drug resistance genes that include: 
MGMT, SOX10,  apoptosis genes, DAPkinase, angio-
genesis genes THSB1
•  Invasion related genes TIMP32,5,11
 
However, the impact of  methylation is still under de-
bate1,4,14. 
 
RARβ receptors bind with retinoic acid, which is a bio-
logically active form of  vitamin A. RARβ is important 
for the embryonic period during morphogenesis, cell 
growth and differentiation. The expression of  RARβ 
shows diversity and is expressed at different times dur-
ing the embryonic development of  a mouse’s nervous 
system8. The methylation of  the RARβ gene has been 
reported in intracranial ependymomas during the child-
hood period and in choroid plexus tumors14. However, 
the role of  the hypermethylated RARβ gene has to this 
point not been associated with pathogenesis of  GBMs. 
The RARβ gene methylation within GBMs was only 
reported by Piperi and colleagues and detected 58.8% 
RARβ methylation in 23 cases of  grade II-IV tumors. 
A positive correlation between RARβ methylation and 
tumor grade in the GBMs was demonstrated and they 
also showed an association between the RARβ meth-
ylation and the aggressive phenotype in the primary 
GBM11. However, there is not sufficient data regarding 
the role of  RARβ in GBM.
 
In our study, we aimed to determine the relationship 
between the methylation of  the tumor suppressor gene 
RARβ with tumor growth, treatment response and 
survival time in GBM. The additional purpose of  this 
study was to determine the effectiveness of  the Meth-
ylation-Specific High Resolution Melting (MS-HRM) 
method for evaluation of  the methylation, which is a 
newly developed application. According to our knowl-
edge, there has been only one publication in the lit-
erature regarding RARβ methylation in GBM cases. 
Therefore, our study group will form a basis for global 
literature for determining the RARβ methylation fre-
quency in GBM patients.
 
Materials and method         
We studied the frequency of  RARβ methylation in a 
series of  40 primary GBM patients in the Turkish pop-
ulation according to patient age, gender, GBM type and 
survival time. Tumor samples were collected during 
surgical resection by the Department of  Neurosurgery. 
Informed consent was obtained from each of  the pa-
tients and the study was approved by the local ethics 
committee. Both the clinical and radiologic data was 
carefully reviewed, compared, and correlated with the 
histopathological results. Clinical data included gender, 
date of  birth, Karnofsky performance score (KPS) and 
type of  treatment (surgical resection — gross total, sub-
total, partial, as per radiologic report; radiotherapy and/
or chemotherapy). The samples included frozen tissues, 
which were collected upon surgical removal.  Our study 
group included female and male patients, where the av-
erage age of  the women was 51.71 ± 3.98 and the aver-
age age of  the men was 58.07 ± 2.71.
The DNA isolation and bisulfate modification meth-
ods were performed as described previously6. A Light-
Cycler ® 480 real time PCR (Roche) device was used 
during implementation of  the processes at this stage. 
PCR amplification and high resolution melting analysis 
was conducted using the “LightCycler ® 480 High Res-
olution Melting Master” kit, which is compatible with 
the device, and was applied according to the manufac-
turer’s protocol.  In our study, we examined the meth-




methylated RARβ primer            




5’-AACCAATCCAACCAAAACAA-3’ (antisense)           
 
A mixture was prepared for the RARβ promoter meth-
ylation analysis using the DNA samples with completed 
bisulfite modification, as described in the user guide for 
the LightCycler Probe Master Mix.
 
Determination of  RARβ methylation status 
The bisulfite modification was applied according to the 
manufacturers’ protocol. After conversion, the DNA 
was eluted in buffer (Qiagen) to a final concentration 
of  30 ng/μl. universal methylated (25%, 50%, 75% 
and 100% methylated control) and unmethylated DNA 
(Chemicon International, Temecula, CA, USA) were 
used as methylated and unmethylated controls. We used 
MS-HRM to detect the methylation levels of  our pa-
tients. The MS-HRM analysis was performed according 
to the LightCycler®480 High Resolution Melting Mas-
ter kits’ protocol. The methylation levels for the RARβ 
gene were compared with the databases “Tm Calling”, 
‘Gene Scanning’’ and‘’Difference plot’.  Similar findings 
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were obtained from all three databases for each of  the 
samples.  The Tm Calling database was used during the 
presentation of  the data. In this analysis method, nor-
malized melting profiles were compared directly along 
with the methylation level of  the DNA sample and 
the methylated / unmethylatedrates were evaluated in 
comparison to established standard melting profiles. In 
this algorithm, the melting temperature curve of  PCR 
products of  the selected cases was compared with the 
melting temperature curve of  the control PCR prod-
ucts with a known rate of  unmethylated to methylat-
ed controls. The results from the methylated and un-
methylated control DNA peaks were compared with 
the DNA samples of  the patients and consequently the 
methylation pattern of  each sample was determined. 
 
Statistical analyses
The statistical analyses were performed by chi-square 
test (x2), two-tailed Fisher’s exact test and T-test. The 
overall survival (OS) time was calculated as the time in 
months between surgery and day of  death. The log-
rank test was used for univariate analysis to estimate dif-
ferences in survival time for RARβ methylation status 
according to the Kaplan–Meier method. Calculations 
were performed using SPSS 15.0 software (SPSS, Chi-
cago, IL, USA), with a statistical significance of  p<0.05.
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Results
Methylation Specific HRM was performed on 40 pri-
mary GBM patients and RARβ methylation status was 
successfully determined in all of  the cases. The average 
age of  the female patients was 51.71 ± 3.98 and the av-
erage age of  the male patients was 58.07 ± 2.71. RARβ 
methylation was detected in 24 (60%) out of  40 cases 
with glioblastoma multiforme in different quantitative 
ratios (Figure 1). 
Both T-test and chi-square test were conducted to eval-
uate RARβ methylation according to the age and gen-
der of  the patients, but the results did not show a sig-
nificant relationship (p=0.329, p=0.099). In addition, 
all the samples in our study group were grade IV type 
tumor samples and therefore this parameter was not in-
cluded in the statistical evaluation.
The melting curves of  positive/methylated control and 
negative/unmethylated control samples and their 75%, 
50% and 25%, interpolated samples, according to their 
fluorescent peak, are shown in Figure 2. 
The low melting point indicates the samples of  un-
methylated cytosine nucleotides that were converted to 
uracile nucleotides and the high melting point shows 
methylated cytosine nucleotides.
The melting temperature for the unmethylated sam-
ples was ~760C and for the methylated samples, it was 
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~810C. The melting temperature data for the DNA 
samples and the temperature data for the methylated 
/positive and unmethylated /negative control samples 
were evaluated using the "Tm calling" software pro-
gram. In this algorithm, the melting profiles for the 
methylated and unmethylated samples showed differ-
ences. The methylated DNA had a higher Tm value, 
due to their CpG sequences in the amplicon. Unmeth-
ylated cytosine nucleotides were converted into uracile 
nucleotides by bisulfite modification and therefore they 
had a Tm value (Figure 3).
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The amplification peak for case 27 was at Tm=81.50C, 
which is concordant with the  amplification peak of  
100%  methylated control DNA.  Therefore, the case 
was evaluated as 100% methylated. The amplification 
peak for case 41 was at Tm= ~810C, which corresponds 
with the amplification peak of  75% methylated control 
DNA as shown in figure 3. As a result, the case was 
assessed as 75% methylated. At Tm= ~800C, the am-
plification peak of  case 36 was observed, which is con-
cordant with the amplification peak of  50% methylated 
control DNA.  The case was therefore assessed as 50% 
methylated (Figure 3).
According to the evaluation of  the methylation rates 
for tumor samples from 24 cases,  it was determined 
that 3 were 25% methylated, 5 were 50% methylated, 
4 were 75% methylated and 12 cases showed 100% 
RARβ gene hypermethylation.  The mean survival time 
of  the patients with RARβ methylation was calculated 
to be 19 months and the survival time for unmethylated 
cases was calculated as 15 months (Table 1).
In our study group, 28 patients out of  40 received treat-
ment, however, the remaining 12 cases had no specified 
treatment protocols in their patient files. One of  the 
cases received only chemotherapy treatment, 9 patients 
received only radiotherapy treatment, and the remain-
ing 17 patients received both radiotherapy and chemo-
therapy.
The statistical analysis shows that the RARβ methylated 
patients who received both chemotherapy and radio-
therapy treatment combined had a survival time of  25 
months. The patients who received only radiotherapy 
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Table 1: Mean survival time of our study group according  
methylation rates of RARβ. 
  
                                                                  Survival Time 
(month) 
Methylated RARβ (  n=24) 19 
Unmethylated RARβ ( n= 16) 15 
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or had no treatment protocol had a survival time be-
tween 15-20 months, which demonstrates a significant 
difference (P<0.05) (Figure 4). 
The patients receiving treatment and RARβ genes were 
also evaluated and it was observed that their survival 
time was 22 months (P<0.05) (Table 2, Figure 4).
Significant statistical (P<0.05) difference was observed 
between the survival times of  the patients receiving 
both radiotherapy and chemotherapy treatment and 
the cases with no applied treatment protocol. Our 
study group was statistically analyzed by using the 
Kaplan-Meier test, in order to establish the relationship 
between RARβ gene quantitative methylation rates (un-
methylated, 25%, 50%, 75%, 100% methylated) and pa-
tient survival times. Due to the small number of  cases, 
when we divided the samples into 3 groups - unmethyl-
ated, methylated <50%, methylated > 50% - there was 
no statistically significant difference in survival time be-
tween the patients with methylation levels higher than 
50% and the patients with methylation lower than 50%.
Discussion
DNA methylation can be examined by using MS-PCR, 
sodium bisulfite sequencing methods or many other 
similar methods.  MS-HRM is a fast, easy and sensitive 
method that can detect methylated DNA at the rate of  
0.1% inside an unmethylated DNA sample9,16.
 
In our study, successful results have been achieved in all 
GBM tissue samples with the MS-HRM method. The 
MS-HRM method was compared in terms of  time to 
the MS-PCR methylation method, which we had been 
using in our previous studies. We determined that the 
MS-HRM method was more suitable in routine analysis 
for screening gene methylation quantitatively.
 
We aimed to examine the RARβ gene methylation pat-
tern, which has been studied extensively in recent years 
in different types of  cancer, such as in prostate cancer15, 
carcinoma of  cervix, uteri10, lung cancer, gastric cancer, 
and hematologic neoplasms. However, although a liter-
ature review revealed that there was an impact of  RARβ 
gene hypermethylationon gliomagenesis, there was only 
one study that showed association of  the RARβ pro-
moter methylation in GBM samples. Therefore, the 
research findings obtained in this study were only com-
pared to the data from this particular relevant study. 
Therefore, our data is open to debate. On the other 
hand, it is the first study in Turkey that has searched 
for a relationship between RARβ hypermethylation fre-
quencies in GBM cases.
 
Piperi and colleagues analyzed the methylation status 
of  four genes (VEGF, COX-2, IL-6, IL-9), which were 
associated with tumors in 23 glioma samples and they 
examined the clinical results related to the inflammation 
and angiogenic agents. They reported that the rate of  
RARβ methylation was 58.8 % and the rate of  MGMT-
methylation was 70.58% in the 6 grade II and 17 grade 
IV GBM samples, respectively. They also reported a 
positive correlation between tumor stage, necrosis de-
gree and the RARβ and MGMT methylation rates14. Ac-
cording to the researchers’ results, the methylation rate 
in grade IV GBM cases was only 42%.  In our study, we 
detected a 60% hypermethylation sample, which is the 
same as Piperi and colleagues The researchers in that 
study used the MS-PCR method and it is known that the 
MS-HRM method, which we used in our study, is more 
sensitive for the detection of  low rate methylation1,14,17. 
On the other hand, the limited number of  cases and the 
limited number of  studies may have a negative effect 
on the positive prognostic and predictive impact of  the 
RARβ gene in GBM.  
 
Furthermore, Piperi and colleagues reported RARβ 
methylation detection in all 6 cases of  their early stages 
glioblastoma patients group. This finding shows tha-
tRARβ gene methylation plays a role in the early stages 
of  the carcinogenesis process.  In our study, we only 
evaluated primary GBM cases and therefore we did not 
obtain data in this direction.
 
RARβ is a member of  the thyroid-steroid hormone re-
ceptor family of  nuclear transcriptional regulators. It 
binds to retinoic acid, which is a biologically active form 
of  vitamin A. RARβ is a tumor suppressor gene, which 
has a role in many cellular events that include embryon-
ic morphogenesis, cellular growth, cell differentiation 
and signal transduction14.
 
Olasz and colleagues showed RARβ gene methylation 
in head and neck cancer. They reported that the RARβ 
hypermethylation was correlated with an advanced 
level of  cancer and the gene expression was reduced. 
However, they also reported that allelic loss of  3p24 
RARβ locus (45.2%) did not affect the mRNA level12. 
Furthermore, it was stated that there was no correlation 
between gene expression and RARβ allelic loss in breast 
carcinomas and esophageal cancers. Considering the 
fact that RARβ is tumor suppressor gene, we can know 
that wild type tumor suppressor gene was induced by 
second allele retinoids. However, the increase of  RARβ 
methylation and the significant decrease in gene expres-
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sion indicates that methylation assumes the main role 
in RARβ suppression. Olasz and colleagues suggested 
that methylation pattern analysis of  this gene could be a 
marker for early diagnosis of  cancer12. There have been 
no studies conducted about glial cells in this direction. 
However, Piperi and colleagues detected 100% methyl-
ation in grade II tumor samples in a series of  patients14 
and this raises the question as to whether it is useful as 
an early diagnostic marker for glioblastomas. We believe 
that more studies should be conducted in this direction.
 
On the other hand, RARβ can be a marker for chemo-
therapy as it is an agent in response to retinoic acid and 
together with MGMT methylation also the RARβ meth-
ylation may use to chemotherapy planning in GBM. 
Because up to date the most studied and most known 
marker for GBM chemotherapy planning was MGMT. 
These benefits that are already specified for head, neck 
and breast cancers should also be examined in detail in 
glioblastomas.
The Kaplan-Meier test was performed to analyze the 
survival rate of  our study group. The results showed 
no significant statistical difference between the survival 
time of  the cases with or without methylation. It was 
determined that the mean survival time for the cases 
without methylation was 15 months and for the cases 
with RARβ methylation was 19 months. The study by 
Piperi and colleagues also did not show a statistically sig-
nificant difference between the cases with methylation 
and without methylation in terms of  survival time12. In 
line with the fact that methylation increases with age, 
the patients with and without methylation were com-
pared in terms of  their age in our study. The average 
age of  the patients with positive methylation was 52.7, 
while the average age of  patients without methylation 
was 60.4. 
No statistically significant differences were observed 
between the groups in terms of  average age. However, 
the important aspect of  our study is that we compared 
the survival time of  patients who received treatment 
protocol and the RARβ methylation status. In our study, 
the patients who received both chemotherapy and radi-
otherapy treatment combined had a survival time of  25 
months. The patients who received only radiotherapy 
or had no treatment protocol had a survival time be-
tween 15-20 months, which demonstrates a statistically 
significant difference (P<0.05). Therefore, this infor-
mation is new for glioblastoma treatment planning and 
it also requires independent confirmation with a series 
of  primary GBMs.
In summary, our results demonstrate the role of  the 
RARβ gene in glioma tumorigenesis, with RARβ pro-
moter methylation being of  prognostic value for glio-
blastoma patients.
Conclusions and recommendations
A high frequency of  methylation was determined for 
the RARβ gene methylation in our study group. The 
rate of  methylation in our group was correlated with 
previous literature. It is concluded that the MS-HRM 
application is reliable and applicable for methylation 
studies of  solid tumors. In our study, the mean survival 
times for the patients with or without methylation were 
identified, and the longer survival time was observed in 
the group with the methylated RARβ gene. The results 
of  our study are different from the results of  previ-
ous study in this regard. Therefore, it was determined 
to be a new finding in medical literature. Due to the 
small number of  studies on RARβ gene methylation 
in patients with GBM, we believe that further studies 
should be carried out to examine larger series of  cases 
and their methylation patterns.
 
In summary, our results demonstrated the role of  
RARβ gene in glioma tumorigenesis, with RARβ pro-
moter methylation being a positive prognostic value 
for glioblastoma patients. Furthermore, a positive cor-
relation between RARβ methylation status and radio/
chemotherapy treatment response was observed.
 




MS-HRM: Methylation-sensitive high resolution melt-
ing
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